BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat Biotechnol 2020;38:789-91. [PMID: 32504046 DOI: 10.1038/s41587-020-0577-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 32.5] [Reference Citation Analysis]
Number Citing Articles
1 Maqueda-Alfaro RA, Marcial-Juárez E, Calderón-Amador J, García-Cordero J, Orozco-Uribe M, Hernández-Cázares F, Medina-Pérez U, Sánchez-Torres LE, Flores-Langarica A, Cedillo-Barrón L, Yam-Puc JC, Flores-Romo L. Robust Plasma Cell Response to Skin-Inoculated Dengue Virus in Mice. J Immunol Res 2021;2021:5511841. [PMID: 33997054 DOI: 10.1155/2021/5511841] [Reference Citation Analysis]
2 Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, Yu F. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 2021;6:233. [PMID: 34117216 DOI: 10.1038/s41392-021-00653-w] [Reference Citation Analysis]
3 Zhou ZH, Dharmarajan S, Lehtimaki M, Kirshner SL, Kozlowski S. Early antibody responses associated with survival in COVID19 patients. PLoS Pathog 2021;17:e1009766. [PMID: 34280244 DOI: 10.1371/journal.ppat.1009766] [Reference Citation Analysis]
4 Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, Li SY, Li Y, He YW. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? Sci China Life Sci 2020;63:1833-49. [PMID: 33355886 DOI: 10.1007/s11427-020-1859-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Noy-Porat T, Edri A, Alcalay R, Makdasi E, Gur D, Aftalion M, Evgy Y, Beth-Din A, Levy Y, Epstein E, Radinsky O, Zauberman A, Lazar S, Yitzhaki S, Marcus H, Porgador A, Rosenfeld R, Mazor O. Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies. Antibodies (Basel) 2021;10:45. [PMID: 34842604 DOI: 10.3390/antib10040045] [Reference Citation Analysis]
6 Alfaleh MA, Zawawi A, Al-Amri SS, Hashem AM. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. MAbs 2022;14:2057832. [PMID: 35380919 DOI: 10.1080/19420862.2022.2057832] [Reference Citation Analysis]
7 Erber J, Wiessner JR, Huberle C, Schneider J, Mijočević H, von Bomhard D, Luppa P, Schmid RM, Rasch S, Lahmer T. Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 - A case series. Transfus Apher Sci 2021;:103278. [PMID: 34548246 DOI: 10.1016/j.transci.2021.103278] [Reference Citation Analysis]
8 Wang LL, Yang JW, Xu JF. Coronavirus (SARS-CoV-2) causes lung inflammation and injury. Clin Microbiol Infect 2021:S1198-743X(21)00674-1. [PMID: 34861410 DOI: 10.1016/j.cmi.2021.11.022] [Reference Citation Analysis]
9 Bamberger C, Pankow S, Martínez-Bartolomé S, Diedrich J, Park R, Yates J. The Host Interactome of Spike Expands the Tropism of SARS-CoV-2. bioRxiv 2021:2021. [PMID: 33619478 DOI: 10.1101/2021.02.16.431318] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Beeraka NM, Sadhu SP, Madhunapantula SV, Rao Pragada R, Svistunov AA, Nikolenko VN, Mikhaleva LM, Aliev G. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status. Front Immunol 2020;11:552925. [PMID: 33072093 DOI: 10.3389/fimmu.2020.552925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
11 Chen F, Liu Z, Jiang F. Prospects of Neutralizing Nanobodies Against SARS-CoV-2. Front Immunol 2021;12:690742. [PMID: 34122456 DOI: 10.3389/fimmu.2021.690742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Shalash AO, Hussein WM, Skwarczynski M, Toth I. Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. Adv Sci (Weinh) 2021;8:e2100985. [PMID: 34176237 DOI: 10.1002/advs.202100985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody Responses in COVID-19: A Review. Front Immunol 2021;12:633184. [PMID: 33936045 DOI: 10.3389/fimmu.2021.633184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
14 Lin C, Li Y, Zhang Y, Liu Z, Mu X, Gu C, Liu J, Li Y, Li G, Chen J. Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. Signal Transduct Target Ther 2021;6:198. [PMID: 34006835 DOI: 10.1038/s41392-021-00619-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tada T, Fan C, Chen JS, Kaur R, Stapleford KA, Gristick H, Dcosta BM, Wilen CB, Nimigean CM, Landau NR. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. Cell Rep 2020;33:108528. [PMID: 33326798 DOI: 10.1016/j.celrep.2020.108528] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
16 Zaki MM, Lesha E, Said K, Kiaee K, Robinson-McCarthy L, George H, Hanna A, Appleton E, Liu S, Ng AHM, Khoshakhlagh P, Church GM. Cell therapy strategies for COVID-19: Current approaches and potential applications. Sci Adv 2021;7:eabg5995. [PMID: 34380619 DOI: 10.1126/sciadv.abg5995] [Reference Citation Analysis]
17 Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang W, Yang Y, Chen W, Gao X, You W, Wang XW, Shi Z, Wang Y, Yang XQ, Zhang L, Huang L, Wang Q, Lu J, Yang YL, Guo J, Zhou W, Wan X, Wu C, Wang W, Du J, Nian X, Li XH, Huang S, Shen S, Xia S, Pan A, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine 2021;38:101010. [PMID: 34250456 DOI: 10.1016/j.eclinm.2021.101010] [Reference Citation Analysis]
18 Reis CA, Tauber R, Blanchard V. Glycosylation is a key in SARS-CoV-2 infection. J Mol Med (Berl) 2021;99:1023-31. [PMID: 34023935 DOI: 10.1007/s00109-021-02092-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Lisewski AM. Association between Influenza Vaccination Rates and SARS-CoV-2 Outbreak Infection Rates in OECD Countries. SSRN Journal. [DOI: 10.2139/ssrn.3558270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Jiang M, Kolehmainen P, Kakkola L, Maljanen S, Melén K, Smura T, Julkunen I, Österlund P. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells. Microbiol Spectr 2021;9:e0077421. [PMID: 34378952 DOI: 10.1128/Spectrum.00774-21] [Reference Citation Analysis]
21 Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex WP, Schneidman-Duhovny D, Zhang C, Shi Y. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 2020;370:1479-84. [PMID: 33154108 DOI: 10.1126/science.abe4747] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 26.0] [Reference Citation Analysis]
22 Chen S, Evert B, Adeniyi A, Salla-Martret M, Lua LH, Ozberk V, Pandey M, Good MF, Suhrbier A, Halfmann P, Kawaoka Y, Rehm BHA. Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity. Adv Healthc Mater 2021;:e2102089. [PMID: 34716678 DOI: 10.1002/adhm.202102089] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 [DOI: 10.1101/2020.09.14.295956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Troisi M, Andreano E, Sala C, Kabanova A, Rappuoli R. Vaccines as remedy for antimicrobial resistance and emerging infections. Curr Opin Immunol 2020;65:102-6. [PMID: 33289646 DOI: 10.1016/j.coi.2020.09.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Porto WF. Virtual screening of peptides with high affinity for SARS-CoV-2 main protease. Comput Biol Med 2021;133:104363. [PMID: 33862305 DOI: 10.1016/j.compbiomed.2021.104363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines (Basel) 2021;9:1376. [PMID: 34960121 DOI: 10.3390/vaccines9121376] [Reference Citation Analysis]
27 Pang NY, Pang AS, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res 2021;8:47. [PMID: 34465396 DOI: 10.1186/s40779-021-00342-3] [Reference Citation Analysis]
28 Nawab DH. Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects. Hum Vaccin Immunother 2021;:1-14. [PMID: 34844516 DOI: 10.1080/21645515.2021.1985891] [Reference Citation Analysis]
29 Guttieres D, Sinskey AJ, Springs SL. Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2. Antib Ther 2021;4:60-71. [PMID: 33928236 DOI: 10.1093/abt/tbab006] [Reference Citation Analysis]
30 Gozalbo-Rovira R, Gimenez E, Latorre V, Francés-Gómez C, Albert E, Buesa J, Marina A, Blasco ML, Signes-Costa J, Rodríguez-Díaz J, Geller R, Navarro D. SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. J Clin Virol 2020;131:104611. [PMID: 32882666 DOI: 10.1016/j.jcv.2020.104611] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
31 Travis CR. As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention. Front Immunol 2020;11:591897. [PMID: 33117404 DOI: 10.3389/fimmu.2020.591897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Lo Muzio L, Ambosino M, Lo Muzio E, Quadri MFA. SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature. Int J Environ Res Public Health 2021;18:11001. [PMID: 34682746 DOI: 10.3390/ijerph182011001] [Reference Citation Analysis]
33 Xi Y. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy? Signal Transduct Target Ther 2020;5:203. [PMID: 32934211 DOI: 10.1038/s41392-020-00310-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
34 Mallano A, Ascione A, Flego M. Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. Int Rev Immunol 2021;:1-21. [PMID: 34494500 DOI: 10.1080/08830185.2021.1929205] [Reference Citation Analysis]
35 Muthumani K, Xu Z, Jeong M, Maslow JN, Kalyanaraman VS, Srinivasan A. Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. Transl Med Commun 2021;6:13. [PMID: 34230895 DOI: 10.1186/s41231-021-00093-2] [Reference Citation Analysis]
36 Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615-632. [PMID: 32887954 DOI: 10.1038/s41577-020-00434-6] [Cited by in Crossref: 280] [Cited by in F6Publishing: 257] [Article Influence: 140.0] [Reference Citation Analysis]
37 Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D'ambrozio J, Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M, Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, Shiryaev SA, Altin JA. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV. bioRxiv 2020:2020. [PMID: 32743570 DOI: 10.1101/2020.07.27.222943] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
38 Gao G, Li C, Fan W, Zhang M, Li X, Chen W, Li W, Liang R, Li Z, Zhu X. Brilliant glycans and glycosylation: Seq and ye shall find. Int J Biol Macromol 2021:S0141-8130(21)01713-X. [PMID: 34389387 DOI: 10.1016/j.ijbiomac.2021.08.054] [Reference Citation Analysis]
39 Estep PW, Church GM. Transparency is key to ethical vaccine research. Science 2020;370:1422-3. [PMID: 33335056 DOI: 10.1126/science.abf4851] [Reference Citation Analysis]
40 Furuse Y, Oshitani H. Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. Front Microbiol 2020;11:583252. [PMID: 33042101 DOI: 10.3389/fmicb.2020.583252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020;35:288-301. [PMID: 32783610 DOI: 10.1152/physiol.00019.2020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
42 Shalash AO, Azuar A, Madge HYR, Modhiran N, Amarilla AA, Liang B, Khromykh AA, Hussein WM, Chappell KJ, Watterson D, Young PR, Skwarczynski M, Toth I. Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems. Pharmaceutics 2022;14:856. [DOI: 10.3390/pharmaceutics14040856] [Reference Citation Analysis]
43 Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D'ambrozio J, Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M, Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, Shiryaev SA, Altin JA. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med 2021;2:100189. [PMID: 33495758 DOI: 10.1016/j.xcrm.2020.100189] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 30.0] [Reference Citation Analysis]
44 Butler SE, Crowley AR, Natarajan H, Xu S, Weiner JA, Bobak CA, Mattox DE, Lee J, Wieland-Alter W, Connor RI, Wright PF, Ackerman ME. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. Front Immunol 2020;11:618685. [PMID: 33584712 DOI: 10.3389/fimmu.2020.618685] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
45 Moore JP, Klasse PJ. COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. J Virol 2020;94:e01083-20. [PMID: 32591466 DOI: 10.1128/JVI.01083-20] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 23.5] [Reference Citation Analysis]
46 Shimizu Y, Ito Y, Uotsu N, Yui K. Intake of 25-Hydroxyvitamin D3 May Reduce the Severity of Upper Respiratory Tract Infection: Post hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study. Nutrients 2020;12:E3769. [PMID: 33302570 DOI: 10.3390/nu12123769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Liu X, Drelich A, Li W, Chen C, Sun Z, Shi M, Adams C, Mellors JW, Tseng CT, Dimitrov DS. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine 2020;38:7205-12. [PMID: 33010978 DOI: 10.1016/j.vaccine.2020.09.058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
48 Tharappel AM, Samrat SK, Li Z, Li H. Targeting Crucial Host Factors of SARS-CoV-2. ACS Infect Dis 2020;6:2844-65. [PMID: 33112126 DOI: 10.1021/acsinfecdis.0c00456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
49 Servidio C, Stellacci F. Therapeutic approaches against coronaviruses acute respiratory syndrome. Pharmacol Res Perspect 2021;9:e00691. [PMID: 33378565 DOI: 10.1002/prp2.691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Cai X, Chen M, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Nguyen M, Shi J, Tomatsidou A, Randall G, Missiakas D, Fung J, Chang EB, Penaloza-MacMaster P, Tian B, Huang J. A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. Adv Sci (Weinh) 2021;:e2103240. [PMID: 34761549 DOI: 10.1002/advs.202103240] [Reference Citation Analysis]
51 Scourfield DO, Reed SG, Quastel M, Alderson J, Bart VMT, Teijeira Crespo A, Jones R, Pring E, Richter FC, Burnell SEA; Oxford-Cardiff COVID-19 Literature Consortium . The role and uses of antibodies in COVID-19 infections: a living review. Oxf Open Immunol 2021;2:iqab003. [PMID: 34192270 DOI: 10.1093/oxfimm/iqab003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
52 Chan SW. Current and Future Direct-Acting Antivirals Against COVID-19. Front Microbiol 2020;11:587944. [PMID: 33262747 DOI: 10.3389/fmicb.2020.587944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Da Costa CBP, Cruz ACM, Penha JCQ, Castro HC, Da Cunha LER, Ratcliffe NA, Cisne R, Martins FJ. Using in vivo animal models for studying SARS-CoV-2. Expert Opin Drug Discov 2021;:1-17. [PMID: 34727803 DOI: 10.1080/17460441.2022.1995352] [Reference Citation Analysis]
54 Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, Li C, Wu Y, Jiang Q, Liu Z, Wang Q, Guo Y, Wu J, Gu C, Cai X, Qu D, Mayer CT, Wang X, Jiang S, Ying T, Yuan Z, Xie Y, Wen Y, Lu L, Wang Q. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep 2021;34:108699. [PMID: 33485405 DOI: 10.1016/j.celrep.2021.108699] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
55 Chen MR, Kuo HC, Lee YJ, Chi H, Li SC, Lee HC, Yang KD. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Front Immunol 2021;12:632890. [PMID: 33732254 DOI: 10.3389/fimmu.2021.632890] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
56 Szekely L, Bozoky B, Bendek M, Ostad M, Lavignasse P, Haag L, Wu J, Jing X, Gupta S, Saccon E, Sönnerborg A, Cao Y, Björnstedt M, Szakos A. Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death. Heliyon 2021;7:e07134. [PMID: 34056141 DOI: 10.1016/j.heliyon.2021.e07134] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
57 Mast FD, Navare AT, van der Sloot AM, Coulombe-Huntington J, Rout MP, Baliga NS, Kaushansky A, Chait BT, Aderem A, Rice CM, Sali A, Tyers M, Aitchison JD. Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality. J Cell Biol 2020;219:e202006159. [PMID: 32785687 DOI: 10.1083/jcb.202006159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
58 Govender R, Moodley J, Naicker T. The COVID-19 Pandemic: an Appraisal of its Impact on Human Immunodeficiency Virus Infection and Pre-Eclampsia. Curr Hypertens Rep 2021;23:9. [PMID: 33570681 DOI: 10.1007/s11906-021-01126-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother 2020;16:3055-60. [PMID: 32845733 DOI: 10.1080/21645515.2020.1796425] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
60 Weinstein JB, Bates TA, Leier HC, McBride SK, Barklis E, Tafesse FG. A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. iScience 2022;:103960. [PMID: 35224467 DOI: 10.1016/j.isci.2022.103960] [Reference Citation Analysis]
61 Vardhan S, Sahoo SK. Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamic simulations. J Tradit Complement Med 2021. [PMID: 34926189 DOI: 10.1016/j.jtcme.2021.12.002] [Reference Citation Analysis]
62 Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution. Viruses 2020;12:E1257. [PMID: 33167496 DOI: 10.3390/v12111257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Chen W, Zhang J, Qin X, Wang W, Xu M, Wang LF, Xu C, Tang S, Liu P, Zhang L, Liu X, Zhang Y, Yi C, Hu Z, Yi Y. SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia. Biomed Pharmacother 2020;130:110629. [PMID: 33406577 DOI: 10.1016/j.biopha.2020.110629] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
64 Ghosh S, Malik YS. Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses. Microorganisms 2020;8:E1840. [PMID: 33238451 DOI: 10.3390/microorganisms8111840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
65 Kim SI, Noh J, Kim S, Choi Y, Yoo DK, Lee Y, Lee H, Jung J, Kang CK, Song KH, Choe PG, Kim HB, Kim ES, Kim NJ, Seong MW, Park WB, Oh MD, Kwon S, Chung J. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. Sci Transl Med 2021;13:eabd6990. [PMID: 33397677 DOI: 10.1126/scitranslmed.abd6990] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
66 Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA 2020;324:951-60. [PMID: 32789505 DOI: 10.1001/jama.2020.15543] [Cited by in Crossref: 227] [Cited by in F6Publishing: 215] [Article Influence: 113.5] [Reference Citation Analysis]
67 Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex WP, Schneidman-Duhovny D, Zhang C, Shi Y. Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2. bioRxiv 2020:2020. [PMID: 32869034 DOI: 10.1101/2020.08.24.264333] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
68 Sajna KV, Kamat S. Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. Cytotherapy 2021;23:101-10. [PMID: 32988772 DOI: 10.1016/j.jcyt.2020.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
69 Cai X, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Chen M, Shi J, Chang EB, Penaloza-MacMaster P, Tian B, Huang J. A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2. bioRxiv 2020:2020. [PMID: 33269351 DOI: 10.1101/2020.11.30.404624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
70 White I, Tamot N, Doddareddy R, Ho J, Jiao Q, Harvilla PB, Yang TY, Geist B, Borrok MJ, Truppo MD, Ganesan R, Chowdhury P, Zwolak A. Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment. MAbs 2021;13:1987180. [PMID: 34693867 DOI: 10.1080/19420862.2021.1987180] [Reference Citation Analysis]
71 Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther 2022;7:146. [PMID: 35504917 DOI: 10.1038/s41392-022-00996-y] [Reference Citation Analysis]